NeuroSense Therapeutics Ltd. (NRSN) Research

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Market snapshot

Symbol
NRSN
Price
$0.80
Day change
+14.13%
Market cap
$19.8M
P/E ratio
-3.14x
52-week range
0.63-2.52
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 days

Peer companies

  • CollPlant Biotechnologies Ltd. (CLGN)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • Enlivex Therapeutics Ltd. (ENLV)
  • Klotho Neurosciences, Inc. (KLTO)
  • Minerva Neurosciences, Inc. (NERV)
  • NeurAxis, Inc. (NRXS)
  • Rallybio Corporation (RLYB)
  • Sonnet BioTherapeutics Holdings, Inc. (SONN)

Recent insider activity

  • Ben-Noon Alon — P-Purchase (250000 shares) on 2026-06-16
  • Eisenberg Or — P-Purchase (250000 shares) on 2026-06-16
  • Eisenberg Or — A-Award (200000 shares) on 2026-03-26
  • Eisenberg Or — trade (0 shares) on 2026-03-18
  • Eisenberg Or — trade (0 shares) on 2026-03-18

Open NeuroSense Therapeutics Ltd. (NRSN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.